Date: 2014-09-16
Type of information: Licensing agreement
Compound: glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology
Company: Pfizer (USA - NY) MedGenesis Therapeutix (Canada)
Therapeutic area: Neurodegenerative diseases
Type agreement: licensing
Action mechanism:
Disease: Parkinson's Disease
Details: * On September 16, 2014, MedGenesis Therapeutix, a privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, announced that it has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson\'s disease. MedGenesis is currently running a proof of concept study in Parkinson\'s disease with its aforementioned GDNF and CED technology.
Financial terms: Under the terms of the agreement MedGenesis will receive an upfront option fee and upon exercise of the option by Pfizer will be eligible for further milestone and royalty payments.
Latest news:
